EP3313520A4 - Therapeutic uses of berberine formulations - Google Patents
Therapeutic uses of berberine formulations Download PDFInfo
- Publication number
- EP3313520A4 EP3313520A4 EP16815356.7A EP16815356A EP3313520A4 EP 3313520 A4 EP3313520 A4 EP 3313520A4 EP 16815356 A EP16815356 A EP 16815356A EP 3313520 A4 EP3313520 A4 EP 3313520A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- therapeutic uses
- berberine
- formulations
- berberine formulations
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184024P | 2015-06-24 | 2015-06-24 | |
US15/161,576 US20160263092A1 (en) | 2013-12-19 | 2016-05-23 | Therapeutic uses of berberine formulations |
PCT/US2016/039180 WO2016210230A1 (en) | 2015-06-24 | 2016-06-24 | Therapeutic uses of berberine formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3313520A1 EP3313520A1 (en) | 2018-05-02 |
EP3313520A4 true EP3313520A4 (en) | 2019-01-02 |
Family
ID=57586436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16815356.7A Withdrawn EP3313520A4 (en) | 2015-06-24 | 2016-06-24 | Therapeutic uses of berberine formulations |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP3313520A4 (en) |
JP (1) | JP2018518507A (en) |
KR (1) | KR20180020229A (en) |
CN (1) | CN107921284A (en) |
AU (1) | AU2016282800A1 (en) |
BR (1) | BR112017027897A2 (en) |
CA (1) | CA2990237A1 (en) |
HK (1) | HK1249068A1 (en) |
IL (1) | IL256400A (en) |
MX (1) | MX2018000262A (en) |
RU (1) | RU2733743C2 (en) |
TW (1) | TW201713334A (en) |
WO (1) | WO2016210230A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102563841B1 (en) * | 2017-01-19 | 2023-08-03 | 티더블유아이 바이오테크놀로지 인코포레이티드 | Methods and pharmaceutical compositions for preventing or treating immunoinflammatory skin disorders |
TW201927292A (en) | 2017-12-13 | 2019-07-16 | 大陸商上海小午醫藥科技有限公司 | A method for preventing or treating a disease associated with inhibition of EGFR |
TW201943428A (en) | 2018-04-16 | 2019-11-16 | 大陸商上海岸闊醫藥科技有限公司 | Method for preventing or treating side effects of cancer therapy |
CN109999034A (en) * | 2019-02-11 | 2019-07-12 | 浙江理工大学 | Oncoprotein TNIK kinases targets natural small molecule inhibitor and its application |
CN109806264B (en) * | 2019-04-10 | 2021-04-02 | 江苏海钥医药科技有限公司 | Pharmaceutical composition and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095640A1 (en) * | 2013-12-19 | 2015-06-25 | Twi Biotechnology, Inc. | Berberine formulations and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7404967B2 (en) * | 1994-12-21 | 2008-07-29 | Cosmederm, Inc. | Topical product formulations containing strontium for reducing skin irritation |
US5760096A (en) * | 1996-10-18 | 1998-06-02 | Thornfeldt; Carl R. | Potent penetration enhancers |
KR100258849B1 (en) * | 1998-04-24 | 2000-08-01 | 박원배 | Pharmaceutically useful protoberberine derivative and its salts |
EP1080719A3 (en) * | 1999-09-03 | 2001-04-25 | Active Organics Inc. | Methods for potentiation of efficacy of topical actives by mono-acyl-(lyso)-glycerophosholipids |
US6440465B1 (en) | 2000-05-01 | 2002-08-27 | Bioderm, Inc. | Topical composition for the treatment of psoriasis and related skin disorders |
US9211259B2 (en) * | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US20040146539A1 (en) | 2003-01-24 | 2004-07-29 | Gupta Shyam K. | Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits |
US7205006B2 (en) * | 2003-09-25 | 2007-04-17 | Prime Pharmaceutical Corporation | Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same |
ES2381359T3 (en) | 2003-11-17 | 2012-05-25 | Sederma | Compositions containing mixtures of tetrapeptides and tripeptides |
US20050158404A1 (en) | 2003-11-18 | 2005-07-21 | Goodless Dean R. | Composition and method for treatment of acne |
WO2011000218A1 (en) * | 2009-06-30 | 2011-01-06 | Shuen-Lu Huang | Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders |
-
2016
- 2016-06-24 CA CA2990237A patent/CA2990237A1/en not_active Abandoned
- 2016-06-24 KR KR1020187001673A patent/KR20180020229A/en not_active Application Discontinuation
- 2016-06-24 AU AU2016282800A patent/AU2016282800A1/en not_active Abandoned
- 2016-06-24 BR BR112017027897A patent/BR112017027897A2/en not_active Application Discontinuation
- 2016-06-24 RU RU2018102700A patent/RU2733743C2/en active
- 2016-06-24 TW TW105120086A patent/TW201713334A/en unknown
- 2016-06-24 EP EP16815356.7A patent/EP3313520A4/en not_active Withdrawn
- 2016-06-24 JP JP2017566661A patent/JP2018518507A/en active Pending
- 2016-06-24 MX MX2018000262A patent/MX2018000262A/en unknown
- 2016-06-24 CN CN201680049200.3A patent/CN107921284A/en active Pending
- 2016-06-24 WO PCT/US2016/039180 patent/WO2016210230A1/en active Application Filing
-
2017
- 2017-12-18 IL IL256400A patent/IL256400A/en unknown
-
2018
- 2018-07-10 HK HK18108954.7A patent/HK1249068A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095640A1 (en) * | 2013-12-19 | 2015-06-25 | Twi Biotechnology, Inc. | Berberine formulations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
BR112017027897A2 (en) | 2018-08-28 |
CN107921284A (en) | 2018-04-17 |
AU2016282800A1 (en) | 2018-02-01 |
IL256400A (en) | 2018-02-28 |
CA2990237A1 (en) | 2016-12-29 |
HK1249068A1 (en) | 2018-10-26 |
RU2733743C2 (en) | 2020-10-06 |
RU2018102700A3 (en) | 2019-12-03 |
TW201713334A (en) | 2017-04-16 |
JP2018518507A (en) | 2018-07-12 |
KR20180020229A (en) | 2018-02-27 |
RU2018102700A (en) | 2019-07-25 |
WO2016210230A1 (en) | 2016-12-29 |
EP3313520A1 (en) | 2018-05-02 |
MX2018000262A (en) | 2018-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3313404A4 (en) | Therapeutic compositions, combinations, and methods of use | |
EP3359168A4 (en) | Therapeutic compounds and methods | |
EP3445750A4 (en) | Therapeutic compounds | |
EP3509581A4 (en) | Formulations of (r | |
EP3368033A4 (en) | Honey-cannabinoid therapeutic composition | |
EP3349796A4 (en) | Therapeutic combinations comprising anti-folr1 immunoconjugates | |
EP3102200A4 (en) | Therapeutic compounds and compositions | |
EP3302439A4 (en) | Therapeutic composition | |
EP3240571A4 (en) | Formulation of aglycosylated therapeutic antibodies | |
EP3116898A4 (en) | Use of aav-expressed m013 protein as an anti-inflammatory therapeutic | |
EP3541385A4 (en) | Pharmaceutical formulations | |
HK1249068A1 (en) | Therapeutic uses of berberine formulations | |
EP3380525A4 (en) | Pharmaceutical formulations and methods of use thereof | |
IL285882A (en) | Therapeutic uses of l-4-chlorokynurenine | |
EP3436467A4 (en) | Novel compositions and therapeutic methods | |
EP3454847A4 (en) | Improved drug formulations | |
EP3259254A4 (en) | Therapeutic compounds | |
EP3337463A4 (en) | Pharmaceutical formulations | |
EP3265177A4 (en) | Formulations of hydrophilic compounds | |
EP3506947A4 (en) | Pharmaceutical formulations of regadenoson | |
EP3319980B8 (en) | Formulations for improving the efficacy of hydrophobic drugs | |
IL267279A (en) | Pharmaceutical formulations of suvorexant | |
EP3226882A4 (en) | Therapeutic compositions | |
HK1258765A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
HUE063178T2 (en) | Formulations of copanlisib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180109 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20181203 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 9/00 20060101ALI20181127BHEP Ipc: A61P 17/02 20060101ALI20181127BHEP Ipc: A61P 43/00 20060101ALI20181127BHEP Ipc: A61K 31/473 20060101AFI20181127BHEP Ipc: A61P 17/04 20060101ALI20181127BHEP Ipc: A61P 17/14 20060101ALI20181127BHEP Ipc: A61P 17/00 20060101ALI20181127BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200414 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20230103 |